Business
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of
About this update from Surrozen, Inc.
[{"type":"text","content":"Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase 1a clinical trial in healthy volunteers with safety data expected by the end of 2023 SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2023 financial results and corporate and pipeline updates. “During the first quarter of 2023, following the completion of dosing in multiple cohorts of healthy volunteers, we enrolled the first patient in the Phase 1a clinical trial of SZN-043 in chronic liver disease, and, recently, re-initiated enrollment in the SZN-1326 Phase 1a clinical trial in healthy volunteers,” said Craig Parker, President and Chief Executive Officer of Surrozen. “We look forward to a productive 2023 as we evaluate the initial safety results from SZN-043 and SZN-1326 clinical trials, advance our partnered program and continue to focus on delivering high-value medicines and shareholder value through our innovative technologies for Wnt pathway modulation.“ Research and Development Pipeline Updates SZN-043 Enrollment ongoing in the SZN-043 Phase 1a clinical trial in people with chronic liver disease and healthy volunteers; the company expects safety data by the end of 2023Anticipate initiation of Phase 1b clinical trial in alcoholic hepatitis in 2024 with potential availability of proof-of-concept data in the second half of 2024 SZN-1326 Re-initiated the SZN-1326 Phase 1a clinical trial in healthy volunteers during the second quarter of 2023; enrollment ongoingExpect Phase 1a safety data in healthy volunteers by the end of 2023Anticipate potential proof-of-concept data in ulcerative colitis (Phase 1b) in the second half of 2024 Corporate Updates Results of Recent Corporate Prioritization Activities In January 2023, Surrozen implemented a restructuring plan approved by the board of directors to prioritize and focus resources on key clinical and discovery programs. The plan included a reduction of the overall workforce by approximately 25%. The company completed the workforce reduction in the first quarter of 20...